NO20053649L - Kombinasjonsterapi - Google Patents
KombinasjonsterapiInfo
- Publication number
- NO20053649L NO20053649L NO20053649A NO20053649A NO20053649L NO 20053649 L NO20053649 L NO 20053649L NO 20053649 A NO20053649 A NO 20053649A NO 20053649 A NO20053649 A NO 20053649A NO 20053649 L NO20053649 L NO 20053649L
- Authority
- NO
- Norway
- Prior art keywords
- combination
- combination therapy
- cpt
- cancer
- antiangiogenic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Foreliggende oppfinnelse angår en metode for å frembringe en antiangiogen og/eller vaskulær permeabilitetsreduserende effekt hos et varmblodig dyr så som et menneske, som eventuelt behandles med ioniserende stråling, spesielt en metode for behandling av kreft, spesielt kreft som involverer en fast tumor, som omfatter én av: administrering av ZD6474 i kombinasjon med 5-FU; administrering av ZD6474 i kombinasjon med CPT-11; og administrering av ZD6474 i kombinasjon med 5-FU og CPT-11; et farmasøytisk preparat omfattende én av: ZD6474 og 5-FU; ZD6474 og CPT-11; og ZD6474 og 5-FU og CPT-11; et kombinasjonsprodukt omfattende én av: ZD6474 og 5-FU; ZD6474 og CPT-11; og ZD6474 og 5 -FU og CPT- I1, for anvendelse ved en metode for behandling av en menneske- eller dyrekropp ved terapi; et sett omfattende én av: ZD6474 og 5-FU; ZD6474 og CPT- 11; og ZD6474 og 5-FU og CPT-11; anvendelse av én av: ZD6474 og 5-FU; ZD6474 og CPT-11; og ZD6474 og 5-FU og CPT-11 ved fremstilling av et medikament for anvendelse for å frembringe en antiangiogen og/eller vaskulær permeabilitetsreduserende effekt hos et varmblodig dyr så som et menneske som eventuelt behandles med ioniserende stråling.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0303289A GB0303289D0 (en) | 2003-02-13 | 2003-02-13 | Combination therapy |
GB0314100A GB0314100D0 (en) | 2003-06-18 | 2003-06-18 | Combination therapy |
GB0316184A GB0316184D0 (en) | 2003-07-10 | 2003-07-10 | Combination therapy |
GB0318311A GB0318311D0 (en) | 2003-08-05 | 2003-08-05 | Combination therapy |
PCT/GB2004/000550 WO2004071397A2 (en) | 2003-02-13 | 2004-02-11 | Combination therapy of zd6474 with 5-fu or/and cpt-11 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20053649D0 NO20053649D0 (no) | 2005-07-27 |
NO20053649L true NO20053649L (no) | 2005-09-12 |
NO331486B1 NO331486B1 (no) | 2012-01-16 |
Family
ID=32872851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20053649A NO331486B1 (no) | 2003-02-13 | 2005-07-27 | Anvendelse av 4-(4-brom-2-fluoranilino)-6-metoksy-7-(1-metylpiperidin-4-ylmetoksy)kinazolin ogsa kjent som ZD6474, eller et farmasoytisk akseptabelt salt derav og ±n av: a) 5-FU; b)CPT-11; og c)5-FU og CPT-11, ved fremstilling av et medikament for anvendelse ved behandling av kreft hos et varmblodig dyr sa som et menneske, samt farmasoytisk preparat og sett inneholdende samme |
Country Status (18)
Country | Link |
---|---|
US (4) | US20060142316A1 (no) |
EP (1) | EP1592423B1 (no) |
JP (3) | JP2006517575A (no) |
KR (2) | KR20110006699A (no) |
AT (1) | ATE506062T1 (no) |
AU (1) | AU2004212255B2 (no) |
CA (1) | CA2514227C (no) |
CY (1) | CY1111565T1 (no) |
DE (1) | DE602004032310D1 (no) |
DK (1) | DK1592423T3 (no) |
HK (1) | HK1084032A1 (no) |
IL (1) | IL169702A (no) |
MX (1) | MXPA05008583A (no) |
NO (1) | NO331486B1 (no) |
NZ (1) | NZ541297A (no) |
PT (1) | PT1592423E (no) |
SI (1) | SI1592423T1 (no) |
WO (1) | WO2004071397A2 (no) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100376567C (zh) | 1999-11-05 | 2008-03-26 | 阿斯特拉曾尼卡有限公司 | 作为vegf抑制剂的喹唑啉衍生物 |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
DK1592423T3 (da) * | 2003-02-13 | 2011-06-27 | Astrazeneca Ab | Kombinationsterapi af ZD6474 med 5-FU og/eller CPT-11 |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
NZ544458A (en) * | 2003-07-10 | 2009-04-30 | Astrazeneca Ab | Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
JP2008501677A (ja) * | 2004-06-04 | 2008-01-24 | ファイザー・プロダクツ・インク | 異常な細胞増殖を治療する方法 |
BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
DK1971338T3 (da) * | 2005-12-22 | 2011-05-23 | Astrazeneca Ab | Kombination af ZD6474 og pemetrexed |
JP2010504949A (ja) * | 2006-09-29 | 2010-02-18 | アストラゼネカ アクチボラグ | Zd6474とベバシズマブの癌療法のための組合せ |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100376567C (zh) * | 1999-11-05 | 2008-03-26 | 阿斯特拉曾尼卡有限公司 | 作为vegf抑制剂的喹唑啉衍生物 |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
BR0313116A (pt) * | 2002-08-09 | 2005-07-05 | Astrazeneca Ab | Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como humano, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável. |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
DK1592423T3 (da) * | 2003-02-13 | 2011-06-27 | Astrazeneca Ab | Kombinationsterapi af ZD6474 med 5-FU og/eller CPT-11 |
NZ544458A (en) * | 2003-07-10 | 2009-04-30 | Astrazeneca Ab | Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability |
BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
JP4834985B2 (ja) * | 2004-12-10 | 2011-12-14 | 日産自動車株式会社 | 組電池の容量調整装置 |
DK1971338T3 (da) * | 2005-12-22 | 2011-05-23 | Astrazeneca Ab | Kombination af ZD6474 og pemetrexed |
JP2010504949A (ja) * | 2006-09-29 | 2010-02-18 | アストラゼネカ アクチボラグ | Zd6474とベバシズマブの癌療法のための組合せ |
-
2004
- 2004-02-11 DK DK04710081.3T patent/DK1592423T3/da active
- 2004-02-11 WO PCT/GB2004/000550 patent/WO2004071397A2/en active IP Right Grant
- 2004-02-11 NZ NZ541297A patent/NZ541297A/en not_active IP Right Cessation
- 2004-02-11 KR KR1020107027024A patent/KR20110006699A/ko not_active Application Discontinuation
- 2004-02-11 EP EP04710081A patent/EP1592423B1/en not_active Expired - Lifetime
- 2004-02-11 JP JP2006502268A patent/JP2006517575A/ja not_active Withdrawn
- 2004-02-11 DE DE602004032310T patent/DE602004032310D1/de not_active Expired - Lifetime
- 2004-02-11 AU AU2004212255A patent/AU2004212255B2/en not_active Ceased
- 2004-02-11 SI SI200431690T patent/SI1592423T1/sl unknown
- 2004-02-11 PT PT04710081T patent/PT1592423E/pt unknown
- 2004-02-11 AT AT04710081T patent/ATE506062T1/de active
- 2004-02-11 US US10/543,106 patent/US20060142316A1/en not_active Abandoned
- 2004-02-11 KR KR1020057014913A patent/KR20050100683A/ko active Search and Examination
- 2004-02-11 CA CA2514227A patent/CA2514227C/en not_active Expired - Fee Related
- 2004-02-11 MX MXPA05008583A patent/MXPA05008583A/es active IP Right Grant
-
2005
- 2005-07-17 IL IL169702A patent/IL169702A/en not_active IP Right Cessation
- 2005-07-27 NO NO20053649A patent/NO331486B1/no not_active IP Right Cessation
-
2006
- 2006-04-11 HK HK06104405.5A patent/HK1084032A1/xx not_active IP Right Cessation
-
2009
- 2009-07-13 US US12/501,599 patent/US20100130520A1/en not_active Abandoned
-
2010
- 2010-10-25 JP JP2010238996A patent/JP5563950B2/ja not_active Expired - Fee Related
- 2010-12-20 US US12/973,271 patent/US20110086870A1/en not_active Abandoned
-
2011
- 2011-06-15 CY CY20111100565T patent/CY1111565T1/el unknown
- 2011-10-27 US US13/282,750 patent/US20120252826A1/en not_active Abandoned
-
2014
- 2014-01-23 JP JP2014010618A patent/JP2014065750A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
NZ541297A (en) | 2008-03-28 |
DK1592423T3 (da) | 2011-06-27 |
MXPA05008583A (es) | 2005-11-04 |
NO20053649D0 (no) | 2005-07-27 |
US20110086870A1 (en) | 2011-04-14 |
ATE506062T1 (de) | 2011-05-15 |
EP1592423A2 (en) | 2005-11-09 |
JP2006517575A (ja) | 2006-07-27 |
US20100130520A1 (en) | 2010-05-27 |
HK1084032A1 (en) | 2006-07-21 |
AU2004212255B2 (en) | 2007-07-05 |
CY1111565T1 (el) | 2015-10-07 |
EP1592423B1 (en) | 2011-04-20 |
CA2514227A1 (en) | 2004-08-26 |
KR20050100683A (ko) | 2005-10-19 |
JP2014065750A (ja) | 2014-04-17 |
DE602004032310D1 (de) | 2011-06-01 |
WO2004071397A3 (en) | 2004-10-14 |
US20120252826A1 (en) | 2012-10-04 |
JP2011016853A (ja) | 2011-01-27 |
AU2004212255A1 (en) | 2004-08-26 |
NO331486B1 (no) | 2012-01-16 |
US20060142316A1 (en) | 2006-06-29 |
IL169702A0 (en) | 2007-07-04 |
SI1592423T1 (sl) | 2011-07-29 |
KR20110006699A (ko) | 2011-01-20 |
JP5563950B2 (ja) | 2014-07-30 |
WO2004071397A2 (en) | 2004-08-26 |
IL169702A (en) | 2014-05-28 |
CA2514227C (en) | 2011-08-09 |
PT1592423E (pt) | 2011-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20053649D0 (no) | Kombinasjonsterapi | |
HK1078771A1 (en) | Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer | |
MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
ATE500832T1 (de) | Kombination von zd6474 und pemetrexed | |
MXPA04004355A (es) | Tratamiento de combinacion que comprende zd6474 y un taxano. | |
MX2007005356A (es) | Terapia de combinacion que comprende zd6474 y un antiadrogenico. | |
HRP20080597T3 (en) | Cancer combination therapy comprising azd2171 and zd1839 | |
NO20064755L (no) | Kombinasjonsterapi | |
NO20056171L (no) | Kombinasjonsterapi | |
NO20064754L (no) | Kombinasjonsterapi | |
MXPA05013827A (es) | Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |